Original Article
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies
Tofacitinib, un inhibidor oral de la cinasa Janus, en pacientes Mexicanos con Artritis Reumatoide: análisis de eficacia y seguridad de estudios fase 3 y de extensión a largo plazo
Ruben Burgos-Vargasa, Mario Cardielb, Daniel Xibilléc, César Pacheco-Tenad, Virginia Pascual-Ramose, Carlos Abud-Mendozaf, Ehab Mahgoubg, Mahboob Rahmanh,◊, Haiyun Fani, Ricardo Rojoi, Erika Garcíag,◊, Karina Santanaj,
Autor para correspondencia
a Hospital General de México, Ciudad de México, Mexico
b Centro de Investigación Clínica de Morelia, Morelia, Mexico
c Servicios de Salud de Morelos, Morelos, Mexico
d Universidad Autónoma de Chihuahua, Chihuahua, Mexico
e Instituto Nacional de Ciencias, Ciudad de México, Mexico
f Hospital Central, San Luis Potosí, Mexico
g Pfizer Inc., Collegeville, PA, USA
j Pfizer Inc., Ciudad de México, Mexico
Ver másLeído
8162
Vecesse ha leído el artículo
3026
Total PDF
5136
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 4 | 14 | 18 |
| 2025 5 | 102 | 53 | 155 |
| 2025 4 | 78 | 35 | 113 |
| 2025 3 | 78 | 41 | 119 |
| 2025 2 | 74 | 40 | 114 |
| 2025 1 | 81 | 60 | 141 |
| 2024 12 | 38 | 31 | 69 |
| 2024 11 | 67 | 54 | 121 |
| 2024 10 | 73 | 40 | 113 |
| 2024 9 | 72 | 19 | 91 |
| 2024 8 | 79 | 36 | 115 |
| 2024 7 | 60 | 35 | 95 |
| 2024 6 | 62 | 32 | 94 |
| 2024 5 | 52 | 38 | 90 |
| 2024 4 | 62 | 23 | 85 |
| 2024 3 | 44 | 38 | 82 |
| 2024 2 | 35 | 23 | 58 |
| 2024 1 | 37 | 25 | 62 |
| 2023 12 | 52 | 39 | 91 |
| 2023 11 | 61 | 34 | 95 |
| 2023 10 | 44 | 30 | 74 |
| 2023 9 | 274 | 40 | 314 |
| 2023 8 | 51 | 18 | 69 |
| 2023 7 | 36 | 18 | 54 |
| 2023 6 | 42 | 22 | 64 |
| 2023 5 | 51 | 22 | 73 |
| 2023 4 | 35 | 16 | 51 |
| 2023 3 | 88 | 31 | 119 |
| 2023 2 | 53 | 38 | 91 |
| 2022 1 | 57 | 20 | 77 |
| 2022 12 | 94 | 33 | 127 |
| 2022 11 | 70 | 29 | 99 |
| 2022 10 | 78 | 48 | 126 |
| 2022 9 | 90 | 45 | 135 |
| 2022 8 | 85 | 50 | 135 |
| 2022 7 | 64 | 44 | 108 |
| 2022 6 | 97 | 44 | 141 |
| 2022 5 | 86 | 58 | 144 |
| 2022 4 | 140 | 54 | 194 |
| 2022 3 | 164 | 52 | 216 |
| 2022 2 | 178 | 34 | 212 |
| 2021 1 | 145 | 48 | 193 |
| 2021 12 | 79 | 43 | 122 |
| 2021 11 | 90 | 49 | 139 |
| 2021 10 | 50 | 69 | 119 |
| 2021 9 | 40 | 48 | 88 |
| 2021 8 | 35 | 48 | 83 |
| 2021 7 | 35 | 47 | 82 |
| 2021 6 | 51 | 45 | 96 |
| 2021 5 | 63 | 51 | 114 |
| 2021 4 | 164 | 59 | 223 |
| 2021 3 | 75 | 45 | 120 |
| 2021 2 | 56 | 30 | 86 |
| 2020 1 | 52 | 25 | 77 |
| 2020 12 | 53 | 30 | 83 |
| 2020 11 | 48 | 25 | 73 |
| 2020 10 | 45 | 25 | 70 |
| 2020 9 | 58 | 37 | 95 |
| 2020 8 | 57 | 24 | 81 |
| 2020 7 | 51 | 33 | 84 |
| 2020 6 | 71 | 11 | 82 |
| 2020 5 | 79 | 24 | 103 |
| 2020 4 | 62 | 23 | 85 |
| 2020 3 | 58 | 33 | 91 |
| 2020 2 | 46 | 32 | 78 |
| 2020 1 | 70 | 30 | 100 |
| 2019 12 | 53 | 34 | 87 |
| 2019 11 | 44 | 14 | 58 |
| 2019 10 | 50 | 22 | 72 |
| 2019 9 | 83 | 32 | 115 |
| 2019 8 | 45 | 31 | 76 |
| 2019 7 | 37 | 27 | 64 |
| 2019 6 | 1 | 0 | 1 |
| 2019 5 | 1 | 0 | 1 |
| 2019 4 | 1 | 2 | 3 |
| 2019 3 | 10 | 4 | 14 |
| 2019 2 | 18 | 2 | 20 |
| 2019 1 | 26 | 22 | 48 |
| 2018 12 | 46 | 50 | 96 |
| 2018 11 | 0 | 18 | 18 |
| 2018 10 | 0 | 16 | 16 |
| 2018 9 | 0 | 7 | 7 |
| 2018 8 | 0 | 22 | 22 |
| 2018 7 | 0 | 4 | 4 |
| 2018 5 | 0 | 2 | 2 |
| 2018 4 | 0 | 15 | 15 |
| 2018 3 | 0 | 25 | 25 |
| 2018 2 | 0 | 17 | 17 |
| 2018 1 | 0 | 12 | 12 |
| 2017 12 | 0 | 21 | 21 |
| 2017 11 | 0 | 19 | 19 |
| 2017 10 | 0 | 25 | 25 |
| 2017 9 | 0 | 30 | 30 |
| 2017 8 | 0 | 27 | 27 |
| 2017 7 | 0 | 36 | 36 |
| 2017 6 | 0 | 93 | 93 |
| 2017 5 | 0 | 7 | 7 |
Mostrar todo
